Skin & hair

Scoring Your Hives So Treatment Can Follow

Save

Hives that come and go by the hour are almost impossible to describe from memory at a fifteen-minute appointment. The UAS7 exists to solve exactly that: a week of two small daily ratings, summed into one figure a clinician can set beside the last one. What follows is how to keep it, and how large a change has to be before it means anything at all.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What does the UAS7 count?

Two things, once a day, for seven consecutive days: how many wheals came up, and how much they itched. Each is rated on a four-point scale from 0 to 3 — none, mild, moderate, intense — so a single day can score anywhere from 0 to 6. Add the seven daily scores together and you have the UAS7, the Urticaria Activity Score summed over a week, running from 0 to 42.

Higher is worse. That is the entire architecture, and its plainness is the point: it can be filled in at the kitchen table in fifteen seconds, on the worst night of a flare, by someone who has not slept. Notice what is not in it — not where the hives were, not what you ate, not whether they left a mark. Two numbers, seven times. The once-daily form is the version urticaria guidelines use and the version that has been formally validated as a measure 1.

Why the diary is yours to keep

Because the hives are gone by the time you get seen. A wheal typically rises, spreads and fades within hours, so an examination at ten on a Tuesday morning is a snapshot of a disease that actually lives in weeks. Most dermatology severity instruments run the other way round — the Severity of Alopecia Tool, for instance, is a clinician's estimate made in the room 2.

The UAS7 hands the pen over, and that changes what makes it accurate. Nobody else can remember your Thursday. It is also why filling in a whole week on the morning of the appointment produces something that looks like data and is not: memory smooths flares toward the average, and that smoothing is precisely what the instrument was built to defeat.

How much change actually counts as change?

About twelve points, for one person. The dedicated validation of the UAS7 — 130 adults with chronic spontaneous urticaria, scored before and after starting omalizumab — reported a minimal important difference of 11 points and a smallest detectable change of 12 1. Those two numbers are doing different jobs, and the gap between them is the most useful thing on this page.

The smallest change that can be told apart from measurement noise (12 points) is slightly larger than the smallest change that feels meaningful to a patient (11) 1.

Read practically: a fall from 30 to 24 is real relief to live through, but it is not yet distinguishable from the ordinary week-to-week wobble of the disease. A fall from 36 to 20 clearly is. This is the honest reason a clinician may want another cycle of diary before changing anything — not indifference, but a floor the instrument itself cannot see beneath.

Once a day, or twice?

Once a day is the version the guidelines use, and the evidence says the shorter route costs nothing. The same validation study compared the once-daily UAS7 against a twice-daily version, the UAS7TD, and found both showed good and comparable clinimetric properties — each correlating closely with the patient's own global assessment of how active the disease was, and with the Urticaria Control Test 1.

The twice-daily form carries its own thresholds, close to mirror images: a minimal important difference of 12 and a smallest detectable change of 11 1. In practice, the choice is about what actually gets completed. A diary scored twice a day and abandoned on Wednesday is worth less than a diary scored once a day for the full seven.

What the score is used for at the appointment

It decides whether to move up the ladder. The joint task force practice parameter for chronic urticaria places second-generation H1-antihistamines first, with escalation of the dose before anything else is added, and add-on agents reserved for disease that stays active despite that 3. A UAS7 is the evidence that disease has stayed active — the thing that turns a step in a guideline into a step in your care.

This is where antihistamine up-dosing gets decided, and it is also where the conversation stalls without numbers. "Still bad" and "a bit better" cannot be graded. A run of weekly totals can: it shows whether the last change did anything, how many weeks it took to show, and whether the improvement held once the initial relief wore off. Chronic hives escalation runs on that sequence far more than on any single visit.

Where the number points past antihistamines

At disease that will not settle on them. Omalizumab, an anti-IgE antibody, was shown in a phase 3 randomised trial to improve itch and urticaria symptoms in people with chronic idiopathic or spontaneous urticaria that had not responded to H1-antihistamines 4. The UAS7 validation itself was carried out around omalizumab initiation, which is a fair signal of where in the pathway this score usually gets pulled out 1.

Antihistamine-resistant hives is the phrase that opens that door, and a documented weekly score is often what has to be in the note before an insurer will look at the request. Whether the next agent is omalizumab vs cyclosporine is a separate conversation with its own trade-offs; the score is what makes it a conversation instead of a shrug.

What the UAS7 leaves out

Deep swelling, first of all. Angioedema — the puffy, often painful swelling of lips, eyelids, hands or feet that frequently travels with hives — is not one of the two items, so a week dominated by swelling and light on wheals can produce a low total that badly misdescribes the week. Writing swelling days in the margin of the diary is the simplest fix, and it changes what the clinician does with the number.

It is also silent on triggers. Inducible urticaria — hives reliably brought on by cold, pressure, exercise, sunlight or firm scratching — behaves differently from spontaneous disease, and a diary of totals alone will bury the pattern that would have named it. It does not measure control or quality of life either; the Urticaria Control Test is a separate instrument for that, and while the two correlate well they are not interchangeable 1. And chronic hives duration is outside it entirely: a UAS7 describes this week, and says nothing about how many more of them there will be.

Keeping a diary that survives real life

The failure mode is not dishonesty, it is Tuesday. A UAS7 collapses when scoring happens whenever it is remembered, so the thing that makes it work is pinning it to something already fixed in the day: same time each evening, same place, one line, whether or not anything happened. A week of zeros is a finding.

  • Score the day that is ending, not the moment you are in. A calm nine o'clock after a wretched afternoon is still a bad day.
  • Count wheals, not patches. Hives merge as they spread, and a single merged plaque was several.
  • Rate itch by what it stopped — sleep, work, sitting still — rather than by a sensation you have to translate into a word.
  • Photograph a bad flare with the date visible. It does not enter the score, but it settles later arguments about what "moderate" meant in week three.
  • Note what else changed that week: a new medicine, an infection, a missed dose, a fever. A total without its context explains nothing.

Bring the whole run rather than a summary. Seven weeks of totals has a shape, and the shape is the finding.

Common questions

In common use, a weekly total above roughly 28 is described as severe activity and one under about 7 as well controlled. Those bands are convention layered onto the scale rather than part of its validation, which defines meaningful change instead. Worth asking which cutoffs your clinic works from, since insurers do not all use the same ones.

All seven is what makes a total comparable to the last one. A week with gaps produces a smaller number that looks like improvement and is not, which is the single most common way a diary misleads. If days were missed, saying so is far more useful than filling them in from memory.

The score is designed to be kept while on treatment — that is exactly what makes it useful, because it shows what the current regimen is and is not holding. Any change to medication is a decision for the clinician prescribing it, and a diary kept through an unplanned gap is worth annotating rather than discarding.

No. The UAS7 counts wheals and itch, so swelling, exhaustion from broken sleep, and the constant low-grade watchfulness of not knowing when the next flare lands are all invisible to it. A low number alongside a wrecked week is worth saying out loud at the appointment rather than filing away.

No. The UAS7 measures how much disease activity happened over the past seven days; the Urticaria Control Test asks how well controlled the condition has been over a longer stretch. They correlate closely in validation work but answer different questions, and some clinics use both because the pair catches what either one alone misses.

Yes. Nothing about the instrument requires paper, and an app that prompts at the same time each evening solves the main reason diaries fail. What matters is that the two daily ratings are recorded consistently and that the raw daily scores can still be seen, not just a chart of the weekly totals.

Related

Deciding about this?

A short, sourced overview to weigh with your clinician:

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Hives that need to be seen the same day

  • —Swelling of the lips, tongue, throat or face, a hoarse or tight voice, or any difficulty breathing or swallowing
  • —Hives together with light-headedness, a racing heart, vomiting, cramping abdominal pain or a sense of impending doom — the pattern of anaphylaxis
  • —Individual wheals that stay in exactly the same spot for more than 24 hours, burn or hurt rather than itch, or fade leaving a bruise or brown stain
  • —Hives arriving with fever, joint pain or swelling, or a general sense of being unwell rather than just itchy

Throat or tongue swelling, trouble breathing or swallowing, or hives with faintness or collapse is a 911 call rather than a drive to urgent care — anaphylaxis moves faster than the journey does.

This page explains how a severity score is constructed and what clinicians do with it. It is general information, not a diagnosis and not a treatment plan, and no score replaces assessment by a clinician who knows your history.

References

  1. 1.Hawro T, Ohanyan T, Schoepke N, et al. (2018). The Urticaria Activity Score-Validity, Reliability, and Responsiveness. The Journal of Allergy and Clinical Immunology: In Practice, 6(4):1185-1190.e1. doi:10.1016/j.jaip.2017.10.001 ✓That the once-daily UAS7 is the guideline-recommended, formally validated version of the instrument; that in 130 adults with chronic spontaneous urticaria assessed around omalizumab initiation it showed a minimal important difference of 11 and a smallest detectable change of 12 (12 and 11 respectively for the twice-daily UAS7TD); and that both versions showed good, comparable clinimetric properties and correlated highly with the Patient Global Assessment of activity and the Urticaria Control Test.
  2. 2.Olsen EA, Hordinsky MK, Price VH, et al. (2004). Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. Journal of the American Academy of Dermatology. doi:10.1016/j.jaad.2003.09.032 ✓The contrast case: that the Severity of Alopecia Tool is a consensus-defined, clinician-rated measure of scalp involvement scored by the examiner, unlike the patient-completed UAS7.
  3. 3.Bernstein JA, Lang DM, Khan DA, et al. (2014). The diagnosis and management of acute and chronic urticaria: 2014 update. Journal of Allergy and Clinical Immunology. PMID 24766875 ✓That the joint task force practice parameter for chronic urticaria places second-generation H1-antihistamines first-line, with dose escalation before further agents, and reserves add-on options for disease that remains active despite that step.
  4. 4.Maurer M, Rosén K, Hsieh HJ, et al. (2013). Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. New England Journal of Medicine. doi:10.1056/NEJMoa1215372 ✓That a phase 3 randomised trial showed omalizumab improves itch and urticaria symptoms in chronic idiopathic or spontaneous urticaria that has not responded to H1-antihistamines.

4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library